Skip to main content
Clinical Trials/EUCTR2021-001730-19-AT
EUCTR2021-001730-19-ATActive, not recruitingPhase 1

Hormones and Muscle– Unravelling the metabolic pathways of endocrine myopathiesA translational magnetic resonance spectroscopy and imaging pilot study - Hormones and Muscle

Medical Univerity of Vienna0 sites83 target enrollmentStarted: January 13, 2022Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
83

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Inclusion criteria (subclinical hypothyroidism):
  • (i) TSH > 4µU/ml, fT4 within the reverence range.
  • (ii) Age between 18 and 70 years
  • (i) Age between 18 and 70 years
  • (ii) Diagnostic criteria fulfilling primary hyperparathyroidism (calcium > 2,5 mmol/l;
  • PTH > upper limit of normal; fractional 24h urinary calcium excretion > 1 %) or hypoparathyroidism (calcium < 2,15 mmol/l; PTH < lower limit of normal)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 83
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • (i) any known disorder of thyroid function, including subclinical and overt hypo- or hyperthyroidism,
  • (ii) positive thyroid autoantibodies (i.e. TRAK, TG-AK, TPO-AK),
  • (iii) current or previous medication for thyroid disorders,
  • (iv) severe metabolic or liver illness (HbA1c > 8%, Triglycerides > 500 mg/dl,
  • Cholesterol > 300 mg/dl, AST & ALT > 3 x upper limit of normal range)
  • (v) pregnancy
  • (vi) breast feeding
  • (vii) general MR-contraindications, including metal devices or other magnetic material
  • hazardous for MR investigation and claustrophobia
  • (viii) statin therapy

Investigators

Sponsor
Medical Univerity of Vienna

Similar Trials